Structural insights into the dual-targeting mechanism of Nutlin-3

Biochem Biophys Res Commun. 2012 Mar 30;420(1):48-53. doi: 10.1016/j.bbrc.2012.02.113. Epub 2012 Feb 28.

Abstract

Multi-targeting therapy is an emerging strategy of drug discovery to improve therapeutic efficacy, safety and resistance profiles. In this study, we monitored the binding of a potent MDM2 inhibitor Nutlin-3 with anti-apoptotic Bcl-2 family proteins using NMR spectroscopy. Our results showed the universal binding of Nutlin-3 with diverse anti-apoptotic Bcl-2 family proteins. Taken together with the binding data for Nutlin-3 analogs, the structural model of the Bcl-X(L)/Nutlin-3 complex showed that the binding mode of Nutlin-3 resembles that of the Bcl-X(L)/Bcl-2 inhibitors, suggesting the molecular mechanism of transcription-independent mitochondrial apoptosis by Nutlin-3. Finally, our structural comparison provides structural insights into the dual-targeting mechanism of how Nutlin-3 can bind to two different target proteins, MDM2 and anti-apoptotic Bcl-2 family proteins in a similar manner.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Apoptosis
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Imidazoles / chemistry*
  • Imidazoles / pharmacology*
  • Nuclear Magnetic Resonance, Biomolecular
  • Piperazines / chemistry*
  • Piperazines / pharmacology*
  • Protein Conformation
  • Proto-Oncogene Proteins c-bcl-2 / chemistry
  • Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-mdm2 / chemistry
  • Structure-Activity Relationship
  • bcl-X Protein / chemistry

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Imidazoles
  • Piperazines
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-X Protein
  • nutlin 3
  • Proto-Oncogene Proteins c-mdm2